EU/3/13/1207

About

On 13 November 2013, orphan designation (EU/3/13/1207) was granted by the European Commission to Amgen Europe BV, the Netherlands, for trebananib for the treatment of ovarian cancer.

Key facts

Active substance
Trebananib
Disease / condition
Treatment of ovarian cancer
Date of first decision
13/11/2013
Outcome
Positive
EU designation number
EU/3/13/1207

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Amgen Europe BV
Minervum 7061
4817 ZK Breda
The Netherlands
Tel. +31 7657 32000
E-mail: medinfoInternational@amgen.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating